Targets › SNF2
1 program from 1 company in 2 trials: 1 Phase 4, 1 Phase 1; Gastroenterology.
Open in Phaseline: the race on SNF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Procter and Gamble | Test Stannous Fluoride Dentifrice Stannous fluoride (0.454%) dentifrice for anti-gingivitis and plaque reduction | SNF2 | Phase 4 | Gingivitis | – |
Gingivitis (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.